Extended Administration of Adjuvant Anatrozole Prolongs DFS in Postmenopausal HR+ Breast Cancer

Treatment with adjuvant anastrozole over a 10-year period remained tolerable and increased disease-free survival rates in postmenopausal women with hormone receptor–positive breast cancer, according to data from the phase 3 AERAS trial.

Related Keywords

Japan , ,Breast Cancer ,Adjuvant Anastrozole ,Postoperative ,Hr Breast Cancer ,Postmenopausal Women ,Phase 3 Aeras Study ,